Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation | Aplastic Anemia and MDS International Foundation

Clinical Trial: NCT01747499

Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
Purpose: 

The purpose of this phase I/II study is to define the maximum tolerated dose of 5-AzaC and the effect on grade II-IV GvHD when given after matched unrelated donor transplant (MUD).

Status: 
Recruiting
Study Date: 
Mon, 04/01/2013 to Sun, 05/01/2016
Bone Marrow Disease(s): 
myelodysplastic syndromes (MDS)
Intervention: 
Drug: Azacitidine Other Names: Vidaza® Ladakamycin 5-AzaC